Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Active mild to moderate distal ulcerative colitis
Last updated February 2, 2024
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Indications
Last updated January 25, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Moderately to severely active Crohn's disease in adults
Last updated January 24, 2024
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Acute bacterial skin and skin structure infections
Last updated January 23, 2024
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Active lupus nephritis
Last updated January 18, 2024
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Systemic lupus erythematosus
Last updated January 18, 2024
Status:
Concluded with an LOI
Manufacturer:
Sobi Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor
Last updated January 17, 2024
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)
Last updated December 21, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 17, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 17, 2023